文献速递其他结缔组织病

利妥昔单抗作为吗替麦考酚酯背景治疗的挽救治疗用于进展性系统性硬化相关间质性肺病

Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression.
PubMed 文献 · Semin Arthritis Rheum · 2020-08-08

该回顾性观察研究纳入24例常规免疫抑制治疗失败后仍进展的系统性硬化相关间质性肺病患者,在吗替麦考酚酯基础上加用利妥昔单抗作为挽救治疗。治疗1年后%pFVC和%pDLCO显著改善,泼尼松剂量显著减少,25%患者可停用泼尼松;完成24个月治疗的15例患者肺功能改善维持。

要点

  • 利妥昔单抗加用于MMF背景可作为常规免疫抑制失败后SSc-ILD的挽救治疗。
  • 治疗1年%pFVC和%pDLCO显著改善,2年时完成治疗者改善维持。
  • 治疗后可显著减少泼尼松剂量,25%患者可停用泼尼松。

核心结论

  • 利妥昔单抗作为MMF的附加治疗,对进展性SSc-ILD表型患者可能是一种有效的挽救治疗。

研究设计与样本

  • 纵向回顾性观察性队列研究,纳入24例常规免疫抑制治疗失败后仍进展的SSc-ILD患者。
  • 所有患者接受至少2个周期利妥昔单抗治疗并评估至少12个月。

主要发现

  • 利妥昔单抗启动前2年内%pFVC和%pDLCO平均下降分别为-12.9%和-12.5%。
  • 治疗1年后%pFVC较基线改善+8.8%(95% CI: -13.7至-3.9;p=0.001),%pDLCO改善+4.6%(95% CI: -8.2至-0.8;p=0.018)。
  • 泼尼松中位剂量显著减少,25%患者可停用泼尼松。
  • 2年时9例停用利妥昔单抗(3例因不良事件,6例因无效)。
  • 完成24个月治疗的15例(62.5%)患者肺功能改善维持:∆%pFVC +11.1%(95% CI: -17.6至-4.5;p=0.003),∆%pDLCO +8.7%(95% CI: -13.9至-8.3;p=0.003)。

临床怎么用

  • 对常规免疫抑制治疗失败后仍进展的SSc-ILD患者,可考虑在MMF基础上加用利妥昔单抗作为挽救治疗。
  • 治疗期间需监测肺功能变化及不良事件,部分患者可能因不良事件或无效而停药。

局限性

  • 本研究为回顾性观察性研究,样本量较小(24例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test whether the use of rituximab (RTX) is effective and safe as a rescue therapy add-on treatment to mycophenolate (MMF) in patients with progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) in whom conventional immunosuppressants (IS) have failed. METHODS: Longitudinal retrospective observational study of a cohort of patients with SSc-ILD that started treatment with RTX due to ongoing lung function impairment despite treatment with glucocorticoids and IS (cyclophosphamide and/or MMF). All patients were treated with 2 or more cycles of RTX and evaluated for at least 12 months. RESULTS: Twenty-four patients were included. Before initiation of RTX the mean decline in%pFVC and %pDLCO during the previous 2 years (delta) was -12.9% and -12.5%, respectively. After 1 year of treatment with RTX, a significant improvement in %pFVC (∆+8.8% compared to baseline, 95% CI: -13.7 to -3.9; p = 0.001) and%pDLCO (∆+4.6%, 95% CI: -8.2 to -0.8; p = 0.018) was observed. In addition, there was a significant reduction in the median dose of prednisone and it could be suspended in 25% of patients. At 2 years of treatment, RTX had been discontinued in 9 patients (due to adverse events in 3 cases and inefficacy in 6). In the 15 patients (62.5%) that completed 24 months of therapy, the statistically significant amelioration in pulmonary function test parameters was maintained: ∆%pFVC: +11.1% (95% CI: -17.6 to -4.5; p = 0.003) and ∆%pDLCO: +8.7% (95% CI: -13.9 to -8.3; p = 0.003). CONCLUSION: Based on our results, RTX's use as an add-on treatment to MMF appears to be effective as a rescue therapy in patients with a more aggressive SSc-ILD phenotype.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Narváez J, LLuch J, Molina-Molina M, et al. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Semin Arthritis Rheum. 2020. PMID: 32911289. doi:10.1016/j.semarthrit.2020.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。